Hemostasis News and Research RSS Feed - Hemostasis News and Research

Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.
Wyss Institute scientists develop better assay for testing hemostasis

Wyss Institute scientists develop better assay for testing hemostasis

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University have devised a better assay for testing blood's clotting tendency, also known as hemostasis, which could one day prove lifesaving in a variety of clinical situations in which a patient's health is jeopardized by abnormal blood coagulation and platelet function. [More]
New $8.5M research grant aims to address patients affected by severe hemophilia A

New $8.5M research grant aims to address patients affected by severe hemophilia A

People with hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency, is the most common form of the genetic disorder caused by missing or defective blood clotting protein called factor VIII. [More]
IL obtains 510(k) clearance for ACL TOP Family 50 Series Hemostasis Testing Systems

IL obtains 510(k) clearance for ACL TOP Family 50 Series Hemostasis Testing Systems

Instrumentation Laboratory today announced the 510(k) clearance of their latest innovation, the ACL TOP Family 50 Series Hemostasis Testing Systems, by the US Food and Drug Administration. [More]
Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company. [More]
New Swabbable Needleless Injection Sites with Barbs from Qosina

New Swabbable Needleless Injection Sites with Barbs from Qosina

Qosina is pleased to announce the addition of three new barbed swabbable needleless injection sites (#80209-#80211), in stock and ready for immediate delivery. [More]
New model of arterial thrombus formation is similar to popular video game

New model of arterial thrombus formation is similar to popular video game

A group of biophysicists, including representatives from MIPT, has developed a mathematical model of arterial thrombus formation, which is the main cause of heart attacks and strokes. [More]
Olympus introduces EZDilate balloon dilator for improved control in endoscopic balloon dilation procedures

Olympus introduces EZDilate balloon dilator for improved control in endoscopic balloon dilation procedures

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today its new 510(k) cleared EZDilate multi-stage endoscopic balloon dilator for improved precision and control in endoscopic balloon dilation procedures. [More]
New Berman Airways from Qosina

New Berman Airways from Qosina

Qosina is pleased to announce the addition of a new line of Berman Airways (#50114 - #50121), in stock and ready for immediate delivery. [More]
Negative impact of high-fat diet on red blood cells may promote development of cardiovascular disease

Negative impact of high-fat diet on red blood cells may promote development of cardiovascular disease

University of Cincinnati researchers have discovered the negative impact a high fat diet has on red blood cells and how these cells, in turn, promote the development of cardiovascular disease. [More]
BMBF provides EUR 25 million to support CTH's Integrated Research and Treatment Centers program

BMBF provides EUR 25 million to support CTH's Integrated Research and Treatment Centers program

An international committee of experts has reviewed and recommended the funding of the Center for Thrombosis and Hemostasis at the Mainz University Medical Center for an additional five years. In accordance with this recommendation, the German Federal Ministry of Education and Research will be providing support of approximately EUR 25 million to the CTH within its Integrated Research and Treatment Centers (IFB) program. [More]
Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States. [More]
Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada. [More]

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Instrumentation Laboratory today announced the commercialization of their HemosIL Rivaroxaban Testing Solution in Europe. The HemosIL Liquid Anti-Xa assay, when used in conjunction with HemosIL Rivaroxaban Calibrators and HemosIL Rivaroxaban controls offers an automated solution for measurement of rivaroxaban. [More]
Mitek Sports Medicine introduces two new arthroscopic surgery radiofrequency devices

Mitek Sports Medicine introduces two new arthroscopic surgery radiofrequency devices

Mitek Sports Medicine, part of DePuy Synthes Companies of Johnson & Johnson, is introducing two new arthroscopic surgery radiofrequency devices this week at the American Orthopaedic Society for Sports Medicine 2015 Annual Meeting. [More]
OBP Medical introduces CLEAR-TRAC family of disposable surgical retractors

OBP Medical introduces CLEAR-TRAC family of disposable surgical retractors

OBP Medical, the leading global developer of single-use, self-contained, illuminating medical devices, today announced the launch of its CLEAR-TRAC family of disposable surgical retractors. The line—which includes CLEAR-TRAC SP (surgical pocket), CLEAR-TRAC V (vaginal) and new CLEAR-TRAC B (breast)—is the first on the market to offer a built-in, single-use light source. [More]
Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen. [More]
Findings could help improve patient care, reduce cancer screening costs around the world

Findings could help improve patient care, reduce cancer screening costs around the world

A large clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa has found that contrary to expectations, a CT scan of the abdomen and pelvis does not improve cancer detection in people with unexplained blood clots in their legs and lungs. [More]

New winged female Luer lock to barb connectors from Qosina

Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery. [More]
Lumenis and top urologists to host instructive workshop series at AUA 2015

Lumenis and top urologists to host instructive workshop series at AUA 2015

Lumenis Ltd., the world's largest energy-based medical device company for surgical, ophthalmology, and aesthetic applications announced today that the company will host an educational symposium, in collaboration with nationally distinguished urologists, and an instructive workshop series at the American Urological Association's (AUA) 2015 Annual Meeting, being held in New Orleans, La., from May 15 – 19, 2015. [More]
First patient enrolled in CryoLife's PerClot IDE clinical trial

First patient enrolled in CryoLife's PerClot IDE clinical trial

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the enrollment of the first patient in its PerClot Investigational Device Exemption (IDE) clinical trial, the Company's pivotal clinical trial to gain approval to commercialize PerClot in the U.S. [More]
Advertisement
Advertisement